Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT06472999
Recruiting Observational

Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury

NCT06472999 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Universität Münster
Phase
Observational
Started
2024-07-24
Last updated
2024-12-12

Condition(s) studied

Acute Kidney Injury

Investigational drug(s) / intervention(s)

Nephroprotective measures

Nephroprotective measures: Due to the observational design of the study, no study specific interventions are performed. The treatment of the patients is completely guided by the responsible physicians.

Study summary

This study investigates to which extent recommended nephroprotective measures are implemented in critically ill patients with moderate or severe acute kidney injury.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Critically ill patients with moderate or severe AKI (KDIGO stage 2 / 3) 2. Requirement of vasopressors or mechanical ventilation 3. Age ≥ 18 years 4. Informed consent Exclusion Criteria: 1. Chronic kidney disease (CKD) with a glomerular filtration rate \< 20ml/min 2. Chronic dialysis dependency 3. History of renal transplantation 4. Permanent ligation of the renal arteries 5. AKI immediately following nephrectomy 6. Patients requiring permanent administration of nephrotoxic drugs (e.g. immunosuppressive therapy afer liver transplantation) 7. Persons with any kind of dependency on the investigator or employed by the sponsor or investigator.

Primary outcome measure(s)

  • Rate of patients in whom "Kidney Disease: Improving Global Outcomes (KDIGO)" guideline recommendations are successfully implemented for 48 hours, following the onset of moderate/ severe AKI (defined by KDIGO criteria) — 60 hours after onset of moderate/severe AKI

Trial sites (3)

FacilityCityRegionStatus
Universitätsklinik Innsbruck Innsbruck Austria Recruiting
University Hospital Münster; Department of Anesthesiology, Intensive Care Medicine and Pain Medicine Münster Germany Recruiting
Radboud University medical cener Nijmegen Netherlands Recruiting

Other trials for the same condition

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 Enrolling by invitation
Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery Recruiting
proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06472999 on ClinicalTrials.gov ↗ ← All trials in the Netherlands